dc.contributor.author | Burns, Margrete Larsen | |
dc.contributor.author | Nikanorova, Marina | |
dc.contributor.author | Baftiu, Arton | |
dc.contributor.author | Rasmussen, Jan Borg | |
dc.contributor.author | Johannessen, Svein Ivar | |
dc.contributor.author | Landmark, Cecilie Johannessen | |
dc.date.accessioned | 2019-03-15T17:22:49Z | |
dc.date.accessioned | 2019-03-22T12:23:55Z | |
dc.date.available | 2019-03-15T17:22:49Z | |
dc.date.available | 2019-03-22T12:23:55Z | |
dc.date.issued | 2019-01-01 | |
dc.identifier.citation | Burns M, Nikanorova M, Baftiu A, rasmussen jb, Johannessen Si, Landmark CJL. Pharmacokinetic variability and clinical use of lacosamide in children and adolescents in Denmark and Norway. Therapeutic Drug Monitoring. 2019:1-26 | en |
dc.identifier.issn | 0163-4356 | |
dc.identifier.issn | 0163-4356 | |
dc.identifier.issn | 1536-3694 | |
dc.identifier.uri | https://hdl.handle.net/10642/6868 | |
dc.description.abstract | Background: The indication for the antiepileptic drug (AED) lacosamide (LCM) was
recently extended to include children from the age of four. Real-life data on the use and
serum concentrations of LCM in children and adolescents are limited. The purpose of this
study was to investigate the use of LCM in this patient group in relation to age, co
medication, dose, serum concentrations and duration of treatment, and to examine
pharmacokinetic variability.
Methods: Children and adolescents (<18 years) who had serum concentrations of LCM
measured from January 2012 to June 2018 were retrospectively identified from the
therapeutic drug monitoring (TDM) databases at two national epilepsy centers in Norway and
Denmark. Clinical data were collected from request forms and medical records.
Results: Data from 124 patients were included, 61 girls/63 boys. Weight was available for 76
patients. Median age was 15 years (range 2-17 years), dose of LCM 300 mg/day (76-600
mg/day) and serum concentration 18 µmol/L (5-138 µmol/L) [4.5 mg/L (1.3-34.5 mg/L)].
Pharmacokinetic variability was demonstrated as the concentration/(dose/kg) ratio ranged
from 1.3 to 9.4 (µmol/L)/(mg/kg) and was affected by age. Polytherapy with 1-3 other AEDs was noted in 107 patients (86%). Treatment was continued beyond 1 year in 71% (n=45) of
the 63 patients where such information was available, and all of these 45 patients had serum
concentrations within the defined reference range. The 1-year retention rate was higher in
patients not concomitantly using other sodium channel blocking drugs (82% vs 56%).
Conclusion: The study demonstrates pharmacokinetic variability in and between age groups,
which indicates usefulness of TDM. More than two thirds of patients continued treatment
beyond one year, suggesting reasonable effectiveness. | en |
dc.language.iso | en | en |
dc.publisher | Lippincott, Williams & Wilkins | en |
dc.relation.ispartofseries | Therapeutic Drug Monitoring;41 (3): 340–347, JUNE 2019 | |
dc.rights | Den aksepterte, fagfellevurderte postprint-versjonen av artikkelene er tillatt å arkivere i institusjonelle arkiv med en embargo på tolv måneder. | en |
dc.subject | Antiepileptic drugs | en |
dc.subject | Lacosamide | en |
dc.subject | Therapeutic drug monitoring | en |
dc.subject | Children | en |
dc.subject | Pharmacokinetic variabilities | en |
dc.title | Pharmacokinetic variability and clinical use of lacosamide in children and adolescents in Denmark and Norway | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2019-03-15T17:22:48Z | |
dc.description.version | acceptedVersion | en |
dc.identifier.doi | http://dx.doi.org/10.1097/FTD.0000000000000599 | |
dc.identifier.cristin | 1685234 | |
dc.source.journal | Therapeutic Drug Monitoring | |